Overview

A Multicenter Prospective Clinical Study of Venetoclax Combined With Azactidine in the Treatment of Acute Leukaemias of Ambiguous Lineage

Status:
Recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

The prognosis of acute leukaemias of ambiguous lineage (ALAL) is poor. The effect of chemotherapy regimen and hematopoietic stem cell transplantation are still unclear. Therefore, we will explore new therapy to improve the remission rate of acute leukaemias of ambiguous lineage. Venetoclax has been approved by FDA for the treatment of AML and CLL/SLL. It can significantly improve the remission rate and prolong PFS and OS. At present, venetoclax combined with azacitidine or decitabine has become the preferred treatment regimen for elderly AML patients. It also shows a high response rate in relapsed/refractory AML or MDS patients. There are few clinical studies on the treatment of ALAL. The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine in the treatment of newly diagnosed ALAL patients.

Phase:

Phase 2

Details

Lead Sponsor:

Sheng-Li Xue, MD

Collaborators:

Affiliated Hospital of Nantong University
First Affiliated Hospital Bengbu Medical College
Jining Medical University
Northern Jiangsu Province People's Hospital
Suzhou Hospital of Traditional Chinese Medicine
The Second People's Hospital of Huai'an

Treatments:

Venetoclax